Paul Ruff to Proportional Hazards Models
                            
                            
                                This is a "connection" page, showing publications Paul Ruff has written about Proportional Hazards Models.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0,603
         
        
        
     
 
    
        
        - 
            Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV. Breast. 2021 Oct; 59:27-36.
            
            
                Score: 0,176
             
- 
            It's contrary - comorbidity does not affect survival of South Africans with colorectal cancer: An analysis from the Colorectal Cancer in South Africa cohort. S Afr Med J. 2020 Apr 29; 110(5):382-388.
            
            
                Score: 0,163
             
- 
            Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer. 2015 Jan; 51(1):18-26.
            
            
                Score: 0,112
             
- 
            The Impact of Breast Cancer Treatment Delays on Survival Among South African Women. Oncologist. 2022 03 11; 27(3):e233-e243.
            
            
                Score: 0,046
             
- 
            Impact of HIV infection on survival among women with stage I-III breast cancer: Results from the South African breast cancer and HIV outcomes study. Int J Cancer. 2022 Jul 15; 151(2):209-221.
            
            
                Score: 0,046
             
- 
            Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Eur J Cancer. 2016 11; 68:51-59.
            
            
                Score: 0,032
             
- 
            Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May; 15(6):569-79.
            
            
                Score: 0,027